ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and non-small cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
ONCOLOGY RESEARCH AND TREATMENT（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要